PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Alkermes plays up responses in mucosal melanoma, but those hoping for an IL-2 renaissance might be disappointed.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.